Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Novozymes

SWX:NZYMB
Snowflake Description

Excellent balance sheet average dividend payer.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
NZYMB
SWX
DKK87B
Market Cap
  1. Home
  2. CH
  3. Materials
Company description

Novozymes A/S produces and sells industrial enzymes and microorganisms worldwide. The last earnings update was 68 days ago. More info.


Add to Portfolio Compare Print
NZYMB Share Price and Events
7 Day Returns
0%
SWX:NZYMB
5.1%
CH Chemicals
10.7%
CH Market
1 Year Returns
-1.7%
SWX:NZYMB
9.7%
CH Chemicals
-5.9%
CH Market
NZYMB Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Novozymes (NZYMB) 0% 0% 0% -1.7% 15.8% -0.3%
CH Chemicals 5.1% -4.1% -8.9% 9.7% 25.4% 42.3%
CH Market 10.7% -7.3% -13.9% -5.9% 2.6% -1.1%
1 Year Return vs Industry and Market
  • NZYMB underperformed the Chemicals industry which returned 9.7% over the past year.
  • NZYMB outperformed the Market in Switzerland which returned -5.9% over the past year.
Price Volatility
NZYMB
Industry
5yr Volatility vs Market

NZYMB Value

 Is Novozymes undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Novozymes to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Novozymes.

SWX:NZYMB Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 16 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 4.4%
Perpetual Growth Rate 10-Year CH Government Bond Rate -0.6%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for SWX:NZYMB
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year CH Govt Bond Rate -0.6%
Equity Risk Premium S&P Global 5.4%
Chemicals Unlevered Beta Simply Wall St/ S&P Global 0.82
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.818 (1 + (1- 22%) (5.4%))
0.901
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.9
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= -0.55% + (0.901 * 5.44%)
4.35%

Discounted Cash Flow Calculation for SWX:NZYMB using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Novozymes is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

SWX:NZYMB DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (DKK, Millions) Source Present Value
Discounted (@ 4.35%)
2020 2,915.34 Analyst x12 2,793.79
2021 3,095.39 Analyst x11 2,842.66
2022 3,255.30 Analyst x11 2,864.87
2023 3,765.00 Analyst x2 3,175.29
2024 3,791.00 Analyst x2 3,063.91
2025 3,801.51 Est @ 0.28% 2,944.31
2026 3,802.62 Est @ 0.03% 2,822.37
2027 3,797.12 Est @ -0.14% 2,700.78
2028 3,787.01 Est @ -0.27% 2,581.29
2029 3,773.70 Est @ -0.35% 2,464.97
Present value of next 10 years cash flows DKK28,254.00
SWX:NZYMB DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= DKK3,773.70 × (1 + -0.55%) ÷ (4.35% – -0.55%)
DKK76,579.16
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= DKK76,579.16 ÷ (1 + 4.35%)10
DKK50,021.34
SWX:NZYMB Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= DKK28,254.00 + DKK50,021.34
DKK78,275.34
Equity Value per Share
(DKK)
= Total value / Shares Outstanding
= DKK78,275.34 / 281.73
DKK277.84
SWX:NZYMB Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in SWX:NZYMB represents 0.14614x of CPSE:NZYM B
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.14614x
Value per Share
(Listing Adjusted, CHF)
= Value per Share (DKK) x Listing Adjustment Factor
= DKK 277.84 x 0.14614
CHF40.60
Value per share (CHF) From above. CHF40.60
Current discount Discount to share price of CHF45.20
= -1 x (CHF45.20 - CHF40.60) / CHF40.60
-11.3%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Novozymes is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Novozymes's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Novozymes's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
SWX:NZYMB PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in DKK DKK11.06
CPSE:NZYM B Share Price ** CPSE (2020-03-31) in DKK DKK309.3
Switzerland Chemicals Industry PE Ratio Median Figure of 5 Publicly-Listed Chemicals Companies 27.4x
Switzerland Market PE Ratio Median Figure of 175 Publicly-Listed Companies 16.61x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Novozymes.

SWX:NZYMB PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= CPSE:NZYM B Share Price ÷ EPS (both in DKK)

= 309.3 ÷ 11.06

27.96x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Novozymes is overvalued based on earnings compared to the CH Chemicals industry average.
  • Novozymes is overvalued based on earnings compared to the Switzerland market.
Price based on expected Growth
Does Novozymes's expected growth come at a high price?
Raw Data
SWX:NZYMB PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 27.96x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 16 Analysts
4.3%per year
Europe Chemicals Industry PEG Ratio Median Figure of 59 Publicly-Listed Chemicals Companies 1.13x
Switzerland Market PEG Ratio Median Figure of 125 Publicly-Listed Companies 1.69x

*Line of best fit is calculated by linear regression .

SWX:NZYMB PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 27.96x ÷ 4.3%

6.46x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Novozymes is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on Novozymes's assets?
Raw Data
SWX:NZYMB PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in DKK DKK40.76
CPSE:NZYM B Share Price * CPSE (2020-03-31) in DKK DKK309.3
Switzerland Chemicals Industry PB Ratio Median Figure of 7 Publicly-Listed Chemicals Companies 3.53x
Switzerland Market PB Ratio Median Figure of 216 Publicly-Listed Companies 1.33x
SWX:NZYMB PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= CPSE:NZYM B Share Price ÷ Book Value per Share (both in DKK)

= 309.3 ÷ 40.76

7.59x

* Primary Listing of Novozymes.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Novozymes is overvalued based on assets compared to the CH Chemicals industry average.
X
Value checks
We assess Novozymes's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Chemicals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Chemicals industry average (and greater than 0)? (1 check)
  5. Novozymes has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

NZYMB Future Performance

 How is Novozymes expected to perform in the next 1 to 3 years based on estimates from 16 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
4.3%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Novozymes expected to grow at an attractive rate?
  • Novozymes's earnings growth is expected to exceed the low risk savings rate of -0.6%.
Growth vs Market Checks
  • Novozymes's earnings growth is positive but not above the Switzerland market average.
  • Novozymes's revenue growth is expected to exceed the Switzerland market average.
Annual Growth Rates Comparison
Raw Data
SWX:NZYMB Future Growth Rates Data Sources
Data Point Source Value (per year)
SWX:NZYMB Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 16 Analysts 4.3%
SWX:NZYMB Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 16 Analysts 4.7%
Switzerland Chemicals Industry Earnings Growth Rate Market Cap Weighted Average 11.9%
Switzerland Chemicals Industry Revenue Growth Rate Market Cap Weighted Average 5.3%
Switzerland Market Earnings Growth Rate Market Cap Weighted Average 8.7%
Switzerland Market Revenue Growth Rate Market Cap Weighted Average 2.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
SWX:NZYMB Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 16 Analyst Estimates (S&P Global) See Below
All numbers in DKK Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
SWX:NZYMB Future Estimates Data
Date (Data in DKK Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 18,357 5,357 4,254 5
2023-12-31 17,486 5,207 4,029 5
2022-12-31 16,227 4,454 3,503 14
2021-12-31 15,523 4,239 3,293 16
2020-12-31 14,861 3,944 3,083 16
2020-03-31
SWX:NZYMB Past Financials Data
Date (Data in DKK Millions) Revenue Cash Flow Net Income *
2019-12-31 14,374 3,196 3,154
2019-09-30 14,357 3,436 3,069
2019-06-30 14,311 3,768 3,238
2019-03-31 14,351 3,558 3,116
2018-12-31 14,390 3,679 3,226
2018-09-30 14,349 3,839 3,183
2018-06-30 14,271 3,649 3,194
2018-03-31 14,311 3,738 3,154
2017-12-31 14,531 4,063 3,119
2017-09-30 14,572 3,963 3,131
2017-06-30 14,382 3,883 3,063
2017-03-31 14,273 4,073 3,077

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Novozymes's earnings are expected to grow by 4.3% yearly, however this is not considered high growth (20% yearly).
  • Novozymes's revenue is expected to grow by 4.7% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
SWX:NZYMB Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 16 Analyst Estimates (S&P Global) See Below

All data from Novozymes Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

SWX:NZYMB Future Estimates Data
Date (Data in DKK Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 16.70 16.70 16.70 1.00
2023-12-31 15.40 15.40 15.40 1.00
2022-12-31 12.92 14.40 11.70 14.00
2021-12-31 11.90 13.20 11.25 15.00
2020-12-31 10.97 11.62 10.59 16.00
2020-03-31
SWX:NZYMB Past Financials Data
Date (Data in DKK Millions) EPS *
2019-12-31 11.06
2019-09-30 10.71
2019-06-30 11.25
2019-03-31 10.78
2018-12-31 11.11
2018-09-30 10.91
2018-06-30 10.91
2018-03-31 10.72
2017-12-31 10.56
2017-09-30 10.56
2017-06-30 10.28
2017-03-31 10.29

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Novozymes is expected to efficiently use shareholders’ funds in the future (Return on Equity greater than 20%).
X
Future performance checks
We assess Novozymes's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Switzerland market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Switzerland market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Novozymes has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

NZYMB Past Performance

  How has Novozymes performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Novozymes's growth in the last year to its industry (Chemicals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Novozymes's year on year earnings growth rate has been positive over the past 5 years.
  • Novozymes's 1-year earnings growth is negative, it can't be compared to the 5-year average.
  • Novozymes's 1-year earnings growth is negative, it can't be compared to the CH Chemicals industry average.
Earnings and Revenue History
Novozymes's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Novozymes Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

SWX:NZYMB Past Revenue, Cash Flow and Net Income Data
Date (Data in DKK Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 14,374.00 3,154.00 2,459.00 1,966.00
2019-09-30 14,357.00 3,069.00 2,492.00 1,959.00
2019-06-30 14,311.00 3,238.00 2,398.00 1,939.00
2019-03-31 14,351.00 3,116.00 2,351.00 1,859.00
2018-12-31 14,390.00 3,226.00 2,334.00 1,852.00
2018-09-30 14,349.00 3,183.00 2,322.00 1,897.00
2018-06-30 14,271.00 3,194.00 2,308.00 1,837.00
2018-03-31 14,311.00 3,154.00 2,382.00 1,849.00
2017-12-31 14,531.00 3,119.00 2,470.00 1,901.00
2017-09-30 14,572.00 3,131.00 2,486.00 1,895.00
2017-06-30 14,382.00 3,063.00 2,468.00 1,887.00
2017-03-31 14,273.00 3,077.00 2,439.00 1,866.00
2016-12-31 14,142.00 3,050.00 2,414.00 1,865.00
2016-09-30 13,880.00 2,936.00 2,434.00 1,841.00
2016-06-30 14,012.00 2,929.00 2,477.00 1,880.00
2016-03-31 14,032.00 2,861.00 2,464.00 1,931.00
2015-12-31 14,002.00 2,823.00 2,462.00 1,896.00
2015-09-30 13,731.00 2,734.00 2,390.00 1,906.00
2015-06-30 13,393.00 2,630.00 2,342.00 1,878.00
2015-03-31 13,005.00 2,539.00 2,324.00 1,812.00
2014-12-31 12,459.00 2,526.00 2,276.00 1,766.00
2014-09-30 12,218.00 2,484.00 2,338.00 1,688.00
2014-06-30 11,970.00 2,413.00 2,311.00 1,614.00
2014-03-31 11,934.00 2,379.00 2,332.00 1,577.00
2013-12-31 11,746.00 2,200.00 2,321.00 1,528.00
2013-09-30 11,617.00 2,132.00 2,253.00 1,533.00
2013-06-30 11,519.00 2,085.00 2,283.00 1,536.00

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Novozymes has efficiently used shareholders’ funds last year (Return on Equity greater than 20%).
  • Novozymes used its assets more efficiently than the CH Chemicals industry average last year based on Return on Assets.
  • Novozymes's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Novozymes's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Chemicals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Novozymes has a total score of 3/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

NZYMB Health

 How is Novozymes's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Novozymes's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Novozymes is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Novozymes's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Novozymes's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 1.7x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Novozymes Company Filings, last reported 3 months ago.

SWX:NZYMB Past Debt and Equity Data
Date (Data in DKK Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 11,480.00 4,086.00 711.00
2019-09-30 11,204.00 3,553.00 651.00
2019-06-30 11,022.00 3,987.00 910.00
2019-03-31 10,928.00 4,281.00 727.00
2018-12-31 11,438.00 3,258.00 723.00
2018-09-30 10,958.00 3,010.00 582.00
2018-06-30 10,720.00 3,423.00 501.00
2018-03-31 10,233.00 3,336.00 716.00
2017-12-31 11,267.00 2,274.00 632.00
2017-09-30 10,736.00 2,312.00 661.00
2017-06-30 10,676.00 2,489.00 647.00
2017-03-31 10,954.00 2,618.00 754.00
2016-12-31 11,745.00 1,803.00 812.00
2016-09-30 10,972.00 1,813.00 675.00
2016-06-30 10,963.00 1,847.00 711.00
2016-03-31 10,633.00 1,984.00 732.00
2015-12-31 11,593.00 1,276.00 839.00
2015-09-30 11,097.00 1,308.00 1,095.00
2015-06-30 11,196.00 1,460.00 1,522.00
2015-03-31 11,268.00 1,382.00 1,172.00
2014-12-31 11,280.00 1,798.00 2,535.00
2014-09-30 11,078.00 1,799.00 3,072.00
2014-06-30 10,833.00 1,879.00 2,840.00
2014-03-31 10,650.00 1,819.00 2,153.00
2013-12-31 11,066.00 1,788.00 1,003.00
2013-09-30 10,590.00 1,827.00 473.00
2013-06-30 10,059.00 2,283.00 395.00
  • Novozymes's level of debt (35.6%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (15.9% vs 35.6% today).
  • Debt is well covered by operating cash flow (78.2%, greater than 20% of total debt).
  • Novozymes earns more interest than it pays, coverage of interest payments is not a concern.
X
Financial health checks
We assess Novozymes's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Novozymes has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

NZYMB Dividends

 What is Novozymes's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
1.7%
Current annual income from Novozymes dividends. Estimated to be 1.96% next year.
If you bought CHF2,000 of Novozymes shares you are expected to receive CHF34 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Novozymes's pays a lower dividend yield than the bottom 25% of dividend payers in Switzerland (2.11%).
  • Novozymes's dividend is below the markets top 25% of dividend payers in Switzerland (4.26%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
SWX:NZYMB Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 16 Analyst Estimates (S&P Global) See Below
Switzerland Chemicals Industry Average Dividend Yield Market Cap Weighted Average of 5 Stocks 2.2%
Switzerland Market Average Dividend Yield Market Cap Weighted Average of 159 Stocks 3.3%
Switzerland Minimum Threshold Dividend Yield 10th Percentile 1.3%
Switzerland Bottom 25% Dividend Yield 25th Percentile 2.1%
Switzerland Top 25% Dividend Yield 75th Percentile 4.3%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

SWX:NZYMB Future Dividends Estimate Data
Date (Data in DKK) Dividend per Share (annual) Avg. No. Analysts
2024-12-31 8.30 1.00
2023-12-31 7.70 1.00
2022-12-31 6.40 12.00
2021-12-31 6.01 15.00
2020-12-31 5.46 13.00
2020-03-31
SWX:NZYMB Past Annualized Dividends Data
Date (Data in DKK) Dividend per share (annual) Avg. Yield (%)
2020-02-26 5.250 1.682
2019-02-27 5.000 1.601
2018-03-13 4.500 1.417
2017-02-22 4.000 1.297
2016-01-19 3.500 1.240
2015-01-20 3.000 0.954
2014-01-21 2.500 0.972
2013-02-27 2.200 1.070
2012-02-29 1.900 1.183
2011-01-21 1.600 0.984
2010-01-25 1.150 0.858
2010-01-21 1.150 1.050

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Dividends per share have been stable in the past 10 years.
  • Dividends per share have increased over the past 10 years.
Current Payout to shareholders
What portion of Novozymes's earnings are paid to the shareholders as a dividend.
  • Dividends paid are well covered by earnings (2.1x coverage).
Future Payout to shareholders
  • Dividends after 3 years are expected to be well covered by earnings (2x coverage).
X
Income/ dividend checks
We assess Novozymes's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.3%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Novozymes afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Novozymes has a total score of 4/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

NZYMB Management

 What is the CEO of Novozymes's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Ester Baiget
TENURE AS CEO 0 years
CEO Bio

Ms. Ester Baiget serves as Chief Executive Officer at Novozymes A/S Since February 1, 2020 and its President since 2020. She serves as the EMEA Commercial Director for Dow Elastomers, Electrical and Telecommunications. Ms. Baiget is responsible for managing the commercial organization, end-use marketing and customer relationships for the business portfolio across the region. She joined Dow in 1995 as an engineer for the LLDPE Solution plant in Tarragona, Spain. In 2000, she joined Europe Polyolefins technical service and development (TS&D) and became a Six Sigma Black Belt, handling a variety of developmental projects. In 2003, she moved to the Dow Fibers Solutions group where she established and consolidated the Global Textile Development Center and, in 2006 she became the technical service leader for the Europe/MEAF Plastics, Elastomers and Rubber Customer Technical Support Center, then was named senior TS&D leader for Basic Plastics in 2008. Since 2009, she served as Global Director of strategic development, and worked directly with the Dow’s office of the Chairman and Chief Executive Officer to support and execute corporate strategy development activities. She serves as Director of MEGlobal B.V. She was named global business director for the ethylene oxide/ethylene glycol (EO/EG) business in 2011, later expanding her responsibilities to include championing the EO derivatives envelope. She assumed her current role in 2012. She holds a chemical engineering degree and an MBA from the University of Tarragona (Spain).

CEO Compensation
  • Insufficient data for Ester to compare compensation growth.
  • Insufficient data for Ester to establish whether their remuneration is reasonable compared to companies of similar size in Switzerland.
Management Team Tenure

Average tenure and age of the Novozymes management team in years:

4
Average Tenure
52
Average Age
  • The tenure for the Novozymes management team is about average.
Management Team

Lars Green

TITLE
Executive VP & CFO
COMPENSATION
DKK4M
AGE
52
TENURE
0.4 yrs

Thomas Videbaek

TITLE
Exectuive VP & COO of Research
COMPENSATION
DKK11M
AGE
59

Andrew Fordyce

TITLE
Executive Vice President of Food & Beverages
COMPENSATION
DKK8M
AGE
56
TENURE
4 yrs

Anders Lund

TITLE
Executive Vice President of Household Care & Technical Industries
COMPENSATION
DKK8M
AGE
46
TENURE
4 yrs

Tina Fanø

TITLE
Executive Vice President of Agriculture & Bioenergy
COMPENSATION
DKK8M
AGE
50
TENURE
4 yrs

Ester Baiget

TITLE
President & CEO

Tobias Bjorklund

TITLE
Head of Investor Relations

Tue Micheelsen

TITLE
Vice President of Global Sales & Marketing

Pedro Fernandes

TITLE
Head of Corporate Affairs & Sustainability - Novozymes Latin America

Sebastian Søderberg

TITLE
VP and Head of New Business Development - Incubations & Acquisitions
Board of Directors Tenure

Average tenure and age of the Novozymes board of directors in years:

7
Average Tenure
57.5
Average Age
  • The tenure for the Novozymes board of directors is about average.
Board of Directors

Jørgen Rasmussen

TITLE
Independent Chairman
COMPENSATION
DKK2M
AGE
64
TENURE
3 yrs

Cees de Jong

TITLE
Vice Chairman
AGE
58

Lars Køppler

TITLE
Employee Representative Director
COMPENSATION
DKK500K
AGE
57
TENURE
10.2 yrs

Mathias Uhlén

TITLE
Independent Director
COMPENSATION
DKK500K
AGE
65
TENURE
13.2 yrs

Lena Holskov

TITLE
Employee Representative Director
COMPENSATION
DKK500K
AGE
52
TENURE
7 yrs

Anders Knudsen

TITLE
Employee Representative Director
COMPENSATION
DKK500K
AGE
60
TENURE
7 yrs

Kasim Kutay

TITLE
Director
COMPENSATION
DKK500K
AGE
54
TENURE
3 yrs

Kim Stratton

TITLE
Independent Director
COMPENSATION
DKK750K
AGE
57
TENURE
3 yrs

Heine Dalsgaard

TITLE
Director
AGE
48

Sharon James

TITLE
Director
AGE
58
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (CHF) Value (CHF)
X
Management checks
We assess Novozymes's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Novozymes has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

NZYMB News

Simply Wall St News

NZYMB Company Info

Description

Novozymes A/S produces and sells industrial enzymes and microorganisms worldwide. The company offers agriculture solutions, including crop production, and animal health and nutrition solutions; liquefaction, saccharifaction, fermentation, lignecellulosic hydrolysis, and process enhancement solutions for bioenergy; baking, beverages, dairy, starch, and protein ingredients for the food and beverage industry; and laundry, dishwashing, hand washing, and cleaning solutions for the household care industry. It also provides wastewater solutions, such as additives, biogas production, industrial bio cleaning, compound removal, odor control, and system start-up solutions; and textile solutions comprising denim finishing and abrasion, biopreparation, biopolishing bleach clean-up, and desizing solutions. In addition, the company offers forest products that include bleach boosting, deinking, fiber modification, effluent control, pitch and stickies control, and starch modification products; and leather solutions, which comprise biopreparation, degreasing, and re-bating. Further, it provides pharmaceutical solutions, including lipases, immobilized lipases, and proteases for biocatalysis; and rTrypsin for cell culture. Novozymes A/S has a strategic collaboration with Boehringer Ingelheim Animal Health for the research, development, production, marketing, and sale of a portfolio of probiotic products; and development agreement with CARBIOS to produce enzyme for recycling of pet-plastics and fibers. The company was founded in 1925 and is headquartered in Bagsvaerd, Denmark.

Details
Name: Novozymes A/S
NZYMB
Exchange: SWX
Founded: 1925
DKK12,380,540,021
281,730,738
Website: http://www.novozymes.com
Address: Novozymes A/S
Krogshoejvej 36,
Bagsvaerd,
Capital Region of Denmark, 2880,
Denmark
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
CPSE NZYM B Series B Shares OMX Nordic Exchange Copenhagen DK DKK 17. Nov 2000
OTCPK NVZM.F Series B Shares Pink Sheets LLC US USD 17. Nov 2000
DB NZM2 Series B Shares Deutsche Boerse AG DE EUR 17. Nov 2000
LSE 0Q4U Series B Shares London Stock Exchange GB DKK 17. Nov 2000
SWX NZYMB Series B Shares SIX Swiss Exchange CH CHF 17. Nov 2000
WBAG NZYM Series B Shares Wiener Boerse AG AT EUR 17. Nov 2000
BMV NZYM N Series B Shares Bolsa Mexicana de Valores MX MXN 17. Nov 2000
BATS-CHIXE NZYMBC Series B Shares BATS 'Chi-X Europe' GB DKK 17. Nov 2000
OTCPK NVZM.Y UNSPONSORED ADR Pink Sheets LLC US USD 24. Feb 2003
Number of employees
Current staff
Staff numbers
5,979
Novozymes employees.
Industry
Specialty Chemicals
Materials
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/03/31 22:23
End of day share price update: 2020/03/31 00:00
Last estimates confirmation: 2020/03/30
Last earnings filing: 2020/01/23
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.